Sign In
Buy GHRS
$23.61
+1.52 (+6.88%)
At Close: Jun 23, 2026
What Makes GH Research (GHRS) a New Buy Stock
01:00pm, Monday, 05'th May 2025
GH Research (GHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
07:00am, Thursday, 27'th Feb 2025
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate
GHRS Stock Rallies 55% in a Week: Here's What You Should Know
11:26am, Thursday, 06'th Feb 2025
GH Research stock soars 55% in a week after the company meets the primary goal in a mid-stage depression study of its lead candidate, GH001.
GH Research Announces Pricing of $150 Million Public Offering
08:52pm, Tuesday, 04'th Feb 2025
DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t
GH Research Announces Proposed Public Offering
04:03pm, Monday, 03'rd Feb 2025
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company, today reported the primary endpoint was met in a randomized, double-blind, placebo
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
04:01pm, Friday, 31'st Jan 2025
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders,
DUBLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders,
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?
10:55am, Wednesday, 20'th Nov 2024
The mean of analysts' price targets for GH Research (GHRS) points to a 225.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
07:00am, Thursday, 14'th Nov 2024
DUBLIN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders,
3 Fast-Growing Stocks Analysts See Doubling in Price
07:16am, Monday, 11'th Nov 2024
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside poten
GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade
01:00pm, Monday, 09'th Sep 2024
GH Research (GHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)
10:35am, Monday, 09'th Sep 2024
GH Research (GHRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisi
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
07:05am, Tuesday, 03'rd Sep 2024
DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders,
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
07:00am, Tuesday, 03'rd Sep 2024
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological d
